

# Sona Balogov

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4808994/sona-balogova-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51  
papers

1,262  
citations

17  
h-index

35  
g-index

63  
ext. papers

1,538  
ext. citations

2.5  
avg, IF

3.82  
L-index

#	Paper	IF	Citations
51	Interference of Known or Suspected Endometriosis in Reporting FDG PET/CT Performed in Another Indication.. <i>Clinical Nuclear Medicine</i> , <b>2022</b> , 47,	1.7	1
50	Hepatic Cavernous Hemangioma Mimicking Metastasis of Midgut Neuroendocrine Neoplasia on 18F-Fluorodihydroxyphenylalanine PET/CT. <i>Clinical Nuclear Medicine</i> , <b>2022</b> , 47, 76-78	1.7	
49	Stage I testicular seminoma risk-adapted therapeutic management. <i>Neoplasma</i> , <b>2021</b> , 68, 613-620	3.3	0
48	Comparison of F-sodium fluoride PET/CT, F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France. <i>BMC Medical Imaging</i> , <b>2020</b> , 20, 25	2.9	3
47	Imagerie du cancer de la prostate oligométastatique, le point de vue du médecin nucléaire. <i>Medecine Nucleaire</i> , <b>2019</b> , 43, 227-235	0.1	1
46	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 2112-2137	8.8	113
45	Prognostic value of functional tumor burden on 68Ga-DOTATOC PET/CT in patients with pancreatic neuro-endocrine tumors. <i>Neoplasma</i> , <b>2019</b> , 66, 140-148	3.3	6
44	18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study. <i>PLoS ONE</i> , <b>2018</b> , 13, e0191487	3.7	14
43	Radiosynoviorthesis of acromioclavicular joint using 169Er-citrate: prospective evaluation of efficacy. <i>Nuclear Medicine Review</i> , <b>2018</b> , 21, 26-31	0.3	3
42	FDG and FCH PET/CT of Multiple Myeloma at Various Clinical Situations: Lesion Detection, Proposal for a Patient-Based "Summ" Score and Reproducibility of Scoring. <i>Blood</i> , <b>2018</b> , 132, 4487-4487	2.2	
41	Guideline for PET/CT imaging of neuroendocrine neoplasms with Ga-DOTA-conjugated somatostatin receptor targeting peptides and F-DOPA. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 1588-1601	8.8	179
40	TEP/TDM au 68 Ga-PSMA-11 quand la 18 F-fluorocholine ne localise pas la récurrence biologique du cancer de la prostate : propos d'un cas et revue de la littérature. <i>Medecine Nucleaire</i> , <b>2017</b> , 41, 453-457	0.1	1
39	Reply. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 172	8.8	
38	18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 1995-2004	8.8	50
37	Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18F-fluorodeoxyglucose on pre-treatment and on interim PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 1220-30	8.8	5
36	Controversies in the management of clinical stage I testicular seminoma. <i>Central European Journal of Urology</i> , <b>2016</b> , 69, 35-9	0.9	2
35	32nd International Austrian Winter Symposium : Zell am See, the Netherlands. 20-23 January 2016. <i>EJNMMI Research</i> , <b>2016</b> , 6, 32	3.6	

34	A Pilot Comparison of 18F-fluorocholine PET/CT, Ultrasonography and 123I/99mTc-sestaMIBI Dual-Phase Dual-Isotope Scintigraphy in the Preoperative Localization of Hyperfunctioning Parathyroid Glands in Primary or Secondary Hyperparathyroidism: Influence of Thyroid Anomalies. <i>Medicine (United States)</i> , <b>2015</b> , 94, e1701	1.8	113
33	Use of choline PET for studying hepatocellular carcinoma. <i>Clinical and Translational Imaging</i> , <b>2014</b> , 2, 103-113	2	12
32	Signification d'une hyperfixation prostatique du fluorodésoxyglucose (18F) chez un patient sans antécédent de cancer de la prostate. Cas cliniques, revue et méta-analyse de la littérature. <i>Medecine Nucleaire</i> , <b>2014</b> , 38, 266-274	0.1	
31	La TEP des tumeurs neuroendocrines de l'intestin grêle. <i>Medecine Nucleaire</i> , <b>2014</b> , 38, 235-239	0.1	
30	Strengths and limitations of using fluorine-fluorodihydroxyphenylalanine PET/CT for congenital hyperinsulinism. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2014</b> , 9, 477-485	4.1	1
29	Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer: a dual centre survey. <i>Radiology and Oncology</i> , <b>2014</b> , 48, 20-8	3.8	7
28	Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism?. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 4531-6	5.6	101
27	Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: a pilot study. <i>Clinical Nuclear Medicine</i> , <b>2014</b> , 39, 951-9	1.7	8
26	Incidental uptake of (18)F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer. <i>Radiology and Oncology</i> , <b>2014</b> , 48, 228-34	3.8	38
25	18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2013</b> , 40, 943-66	8.8	89
24	Effect of erythropoietin on bone marrow uptake of 18F-fluorocholine in prostate cancer: comparison with 18F-fluoride uptake. <i>Clinical Nuclear Medicine</i> , <b>2013</b> , 38, 200-2	1.7	10
23	Can we achieve a radionuclide radiation dose equal to or less than that of 99mTc-hydroxymethane diphosphonate bone scintigraphy with a low-dose 18F-sodium fluoride time-of-flight PET of diagnostic quality?. <i>Nuclear Medicine Communications</i> , <b>2013</b> , 34, 417-25	1.6	20
22	Metabolic syndrome and its effect on aortic stiffness in premenopausal women. <i>Bratislava Medical Journal</i> , <b>2013</b> , 114, 279-82	1.7	1
21	What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma?. <i>Current Radiopharmaceuticals</i> , <b>2013</b> , 6, 96-105	1.8	23
20	Évolution de la demande des examens de médecine nucléaire pour cancer de la prostate depuis l'enregistrement de la fluorocholine (18F) : analyse sur deux ans à l'hôpital Tenon. <i>Medecine Nucleaire</i> , <b>2012</b> , 36, 363-370	0.1	1
19	Étude rétrospective des conséquences de l'administration d'une préparation de FDG contenant de 5% à 10% de fluorure (18F) libre sur l'imagerie TEP/TDM de l'os sain et des foyers osseux pathologiques. Comparaison avec un groupe apparié de patients ayant reçu une préparation de FDG contenant moins de 5% de fluorure (18F) libre. <i>Medecine Nucleaire</i> , <b>2012</b> , 36, 371-377	0.1	
18	TEP/TDM au FDG et hibernome : à propos d'un cas. <i>Medecine Nucleaire</i> , <b>2012</b> , 36, 408-412	0.1	
17	Effet du traitement par pegfilgrastim sur la fixation de la fluorocholine (18F) par la moelle osseuse. <i>Medecine Nucleaire</i> , <b>2012</b> , 36, 413-418	0.1	2

16	Registered and potential indications of FDG PET/CT in breast carcinoma. <i>Archive of Oncology</i> , <b>2012</b> , 20, 152-157	0.2	
15	A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection. <i>Nuclear Medicine Communications</i> , <b>2012</b> , 33, 757-65	1.6	20
14	Diagnosis of bone metastasis: recent comparative studies of imaging modalities. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2011</b> , 55, 374-410	1.4	33
13	Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2011</b> , 55, 448-57	1.4	71
12	Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose. <i>Nuclear Medicine Communications</i> , <b>2010</b> , 31, 389-97	1.6	41
11	Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. <i>Journal of Nuclear Medicine</i> , <b>2010</b> , 51, 1699-706	8.9	153
10	La fluorocholine(18F) a une utilit'clinique dans le cancer de la prostate et le carcinome h'patocellulaireParfois chez le m'ne malade. <i>Medecine Nucleaire</i> , <b>2010</b> , 34, 378-382	0.1	5
9	La concentration plasmatique de PTH permet-elle de s'lectionner les patients atteints d'hyperparathyro'die secondaire pour b'ncifier de la scintigraphie double isotope MIBI (99mTc)/123I pr'op'fatoire?. <i>Medecine Nucleaire</i> , <b>2010</b> , 34, 388-392	0.1	
8	R'cidive biologique de cancer de la prostate : int'f' de la TEP/TDM ^ la fluorocholine (18F) du corps entier. <i>Medecine Nucleaire</i> , <b>2010</b> , 34, 540-545	0.1	2
7	Tomographie d'mission de positons et radiopharmaceutiques sp'cifiques en oncologie : exemples d'application. <i>Medecine Nucleaire</i> , <b>2009</b> , 33, 152-160	0.1	0
6	TEP/TDM au fluorure (18F) de sodium pour la d'tection des m'tastases osseuses du cancer de la prostate. Description de l'ude Fluprostatic de comparaison de la TEP/TDM au fluorure (18F) de sodium ^IRM corps entier dans cette indication. <i>Medecine Nucleaire</i> , <b>2009</b> , 33, 388-397	0.1	2
5	Tomographie par mission de positons et cancer de la prostate. <i>Medecine Nucleaire</i> , <b>2008</b> , 32, 409-417	0.1	3
4	Prospective comparison of FDG and FET PET/CT in patients with head and neck squamous cell carcinoma. <i>Molecular Imaging and Biology</i> , <b>2008</b> , 10, 364-73	3.8	30
3	Impact of FDG-PET to detect recurrence of head and neck squamous cell carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2007</b> , 137, 647-53	5.5	25
2	TEP/TDM ^ la fluorom'thylcholine-(18F) dans l'imagerie de la r'cidive du cancer de la prostate : jalons pour un PHRC national. <i>Medecine Nucleaire</i> , <b>2007</b> , 31, 338-344	0.1	1
1	Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2003</b> , 30, 1266-9	8.8	34